Processa Pharmaceuticals Signs Milestone-Rich Agreement with Intact Therapeutics

Processa Pharmaceuticals shares are trading higher after announcing an exclusive licensing agreement with Intact Therapeutics for their Phase 2 gastroparesis drug candidate, PCS12852, which could bring in significant milestone and royalty payments.